ERT is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. The company delivers a unique combination of technology, services and clinical consulting, built on a foundation of deep scientific and regulatory expertise.

ERT's systems are widely used by pharmaceutical and biotech companies innovating drug and device therapies to optimize clinical trial management, and to document safety and efficacy clinical outcomes data. ERT's solutions increase the accuracy and reliability of patient data and improve widely deployed solutions in healthcare areas such as Cardiac Safety, Respiratory Solutions and electronic Clinical Outcome Assessments (eCOA).

Since its inception in 1972, ERT has developed from a technology start-up to a company that today supports the conduct of thousands of clinical trials annually. This is achieved through the compilation of a variety of clinical outcome data from more than 3 million patients, in strict accordance with the standards defined by the major regulatory agencies.


Nordic Capital Fund VIII acquired ERT in 2016. The ambition is to support ERT's continued development, strategic goals, future growth and further international expansion. Supported by Nordic Capital, ERT will be well positioned to continue its development as a global market leader within innovative and differentiated patient data collection solutions.

Key Information

Revenues Icon

Revenues 2018*

EUR 500 million

Employees Icon



Ownership Icon


Nordic Capital Fund VIII, controlling shareholding

Head Office Icon

Head office

Philadelphia, Pennsylvania, USA

Investment Icon

Investment date